Liquid biopsy biomarkers for bladder cancer: LiqBio-BC

Description

Bladder cancer (BC) is a common public health problem worldwide and a major cause of morbidity and mortality, with significant lifetime treatment costs. Due to the biodiversity of tumours, poor risk stratification, treatment resistance and poor clinical outcomes are frequently observed.

The project will develop an innovative test for non-invasive diagnosis of bladder cancer using epigenetic markers from urinary exosomes. The test will contribute to increasing healthy life years, reducing treatment costs and strengthening the knowledge base through data analytics and MI.

The vision of the project is to shift bladder cancer diagnosis from hospitals to primary care, ensuring earlier detection, better treatment choices, higher survival rates and lower costs for the healthcare system.

Achievable results

The aim of the project is to develop an innovative diagnostic test (medical device) for the non-invasive diagnosis of bladder cancer using epigenetic markers (miRNAs) from urinary exosomes, and to analyse clinical and demographic data with an artificial intelligence algorithm, thereby strengthening the knowledge base.

Benefit

A new diagnostic test (medical device) will be developed that can be used to diagnose bladder cancer, thereby facilitating early detection, making treatment choices easier, improving treatment outcomes and reducing costs for the healthcare system.